Sort
48,018 grants matching “immunotherapy”
Analyses of human T regulatory cells
$680,834Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Immune Signatures and Clinical Outcomes in Acute Pancreatitis
$680,769Georgios I Papachristou · Ohio State University · R01 · FY2025 · DK
Clinical Protocol and Data Management (Core 018)
$680,746Elizabeth C Dees · Univ Of North Carolina Chapel Hill · P30 · FY2016 · CA
Novel regulatory mechanisms and agonists of STING
$680,598Xuewu Zhang · Ut Southwestern Medical Center · R01 · FY2025 · CA
Novel regulatory mechanisms and agonists of STING
$680,598Xuewu Zhang · Ut Southwestern Medical Center · R01 · FY2023 · CA
The Molecular Profile of Prostate Tumors in African-American Men
$680,523Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Cell-free DNA fragmentomics as prognostic and treatment resistance biomarkers in metastatic castration-resistant prostate cancer
$680,453Shuang Zhao · University Of Wisconsin-Madison · R01 · FY2025 · CA
Prostate Cancer Immunotherapy
$680,424Rockefeller University · R01 · FY2003 · CA
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity
$680,292Sharon S Evans · Roswell Park Cancer Institute Corp · R01 · FY2023 · CA
The Variation of the NK Cell Receptome in Pemphigus
$680,271Danillo G Augusto · University Of North Carolina Charlotte · R01 · FY2023 · AI
Drug eluting injectable biomaterials for next generation chemoembolization
$680,198Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2021 · CA
Selective disruption of histone deacetylase complexes using protein interaction modulators
$680,126Marc Vidal · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Mechanism of cell uptake for pathogenic tau seeds
$680,077Marc I Diamond · Ut Southwestern Medical Center · R01 · FY2024 · AG
Mechanism of cell uptake for pathogenic tau seeds
$680,077Marc I Diamond · Ut Southwestern Medical Center · R01 · FY2022 · AG
Mechanism of cell uptake for pathogenic tau seeds
$680,077Marc I Diamond · Ut Southwestern Medical Center · R01 · FY2023 · AG
Innate Immunity Stimulation via CpG ODN in a Non-Human Primate Model of Sporadic Cerebral Amyloid Angiopathy
$680,059Henrieta Scholtzova · New York University School Of Medicine · R01 · FY2017 · NS
Evaluating and Optimizing Novel nSMase2 Inhibitors in the Treatment of Cancers
$680,034Robert H Blelloch · University Of California, San Francisco · R01 · FY2025 · CA
Project 2 Intrathecal Anti-PD-1 Immunotherapy for Metastatic Melanoma Patients with Leptomeningeal Disease (LMD)
$680,004Isabella Claudia Glitza · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
IGF::OT::IGF TESTING OF COMBINATION IMMUNO AND CHEMOPREVENTION STRATEGIES FOR LYNCH SYNDROME GASTROINTESTINAL CANCER
$679,964Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · N01 · FY2015 · CA
Developing new immunotherapies based of CD4 T cells
$679,738Nicholas Restifo · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Evaluating Pathways Involved in Melanoma Initiation
$679,604Leonard I Zon · Boston Children'S Hospital · R01 · FY2025 · CA
Variation in tumor-associated immune profiles and colorectal cancer outcomes
$679,508Stephanie L. Schmit · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · CA
Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge
$679,409Brenda Marie Sandmaier · Fred Hutchinson Cancer Research Center · P01 · FY2021 · CA
Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases
$679,319Ouri Cohen · Sloan-Kettering Inst Can Research · R37 · FY2023 · CA
Targeting the IL-2/regulatory T cell axis for autoimmune disease prevention in realistic animal models
$679,264Daniel J. Campbell · Benaroya Research Inst At Virginia Mason · R01 · FY2021 · AI